Author

Kenneth H. Ngo

Dana-Farber Cancer InstituteORCID 0000-0001-5511-2825Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Marie-Anaïs LocquetiD· 2 shared Prafulla C. GokhaleiD· 2 shared Adrian Gerold SacheriD· 1 shared Alexander SpektoriD· 1 shared Alexander Wang YingiD· 1 shared Andrew T. BockusiD· 1 shared Aniruddha SarkariD· 1 shared Benedikt Mathias KessleriD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Marie-Anaïs LocquetORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 1, 2026

mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion

Claudia Gentile, William W. Feng, Sean M. Lenahan…·Cigall Kadoch

This study shows that inhibiting mSWI/SNF complexes enhances the effectiveness of KRAS inhibitors in lung cancers by reversing epithelial-mesenchymal transition resistance.

DOI 10.64898/2026.02.27.708377

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyJournal of Thoracic OncologyPeer-reviewedAug 1, 2025

Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity

Shilpa Singh, Catherine E. Gleason, Min Fang…·Matthew G. Oser

This paper develops cyclin A/B macrocyclic inhibitors that induce apoptosis in cancers with high E2F activity by blocking RxL-mediated interactions, showing efficacy in SCLC models.

29 citationstop 1%

humanproteomics

𝕏 PostBluesky